Legend Biotech CORP

Legend Biotech Corp. Director Patrick John Casey reported a sale of 6,000 ordinary shares on June 30, 2026, for a total transaction value of $88,800.

Legend Biotech Corp. CEO Ying Huang reported a sale of 5,566 ordinary shares on June 25, 2026, to cover tax obligations.

Legend Biotech Corp's CEO, Huang Ying, sold 9,936 ordinary shares to cover tax obligations related to restricted share unit vesting.

FMR LLC, through its subsidiaries, has disclosed beneficial ownership of 15.0% of Legend Biotech Corp.'s common stock as of June 30, 2026.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 13.1% in Legend Biotech Corp's Ordinary Shares as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 15.0% of Legend Biotech Corp's common stock, totaling over 55 million shares.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 13.9% in Legend Biotech Corp, holding over 51 million common shares as of June 30, 2025.

FMR LLC and its Chairman and CEO, Abigail P. Johnson, have disclosed a combined beneficial ownership of 10.9% in Legend Biotech Corp, totaling over 40 million shares.

T. Rowe Price Associates, Inc. has filed an amendment to its Schedule 13G, disclosing a 3.7% beneficial ownership stake in Legend Biotech Corp-ADR as of December 31, 2024.